<![CDATA[Rhizen Pharmaceuticals S.A. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=36533>Sat, 25 Apr 2026 08:07:33 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020]]>https://www.newswire.co.kr/newsRead.php?no=915398Mon, 07 Dec 2020 10:56:01 +0900<![CDATA[Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020]]>https://www.newswire.co.kr/newsRead.php?no=915126Wed, 02 Dec 2020 10:24:33 +0900